Compare Bristol-Myers Squibb Co (BMY) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs DoorDash Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.94 (market cap $132.45B), while DoorDash Inc trades at $212 (market cap $90.93B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.
| BMY | DASH | |
|---|---|---|
Market Cap | $132.45B | $90.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $281.74 |
52-Week Low | $42.60 | $146.60 |
Enterprise Value | $166.44B | $88.89B |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
DoorDash (DASH) trades at $216.26, up 1.41% with strong technical momentum above key support levels. The company demonstrates robust revenue growth, with Q2 2026 revenue up 36% YoY to $4.45B, though earnings missed estimates due to higher R&D costs. Analyst sentiment remains overwhelmingly positive with 75.68% buy ratings and a $247.41 consensus price target, representing 14.4% upside potential from current levels.
DoorDash's expansion into grocery, retail, and international markets supports growth, but elevated valuation multiples (P/E 113.23) and intense competition present risks. The stock's technical strength and fundamental growth trajectory suggest continued upside, though investors should monitor execution on profitability targets and competitive pressures in the delivery space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
